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Right ventricle (RV) dysfunction is a key outcome determinant and a leading cause of death for patients with
chronic thromboembolic pulmonary hypertension (CTEPH). In this report, we followed the 5-year clinical journey of
a patient with CTEPH. The tricuspid pressure gradient was significantly increased in the early phase of CTEPH and
“normalized” at the late phase of this patient’s clinical journey, but this “normalized” gradient is not a positive
treatment response but rather an ominous sign of advancing right heart failure owing to an exhaustion of RV
contractile function. Thus, appropriate interpretation of the tricuspid pressure gradient change is of importance
for assessing RV dysfunction and treatment outcome during follow-up in patients with CTEPH. Besides systolic
pulmonary artery pressure (SPAP), other RV functional parameters such as tricuspid annular plane systolic excursion,
RV fractional area change, and RV longitudinal strain, together with clinical markers, may provide additional
guidance regarding functional improvement or progression in patients with CTEPH.
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Pulmonary thromboembolism serves as a common cause
of pulmonary hypertension (PH), termed chronic thrombo-
embolic pulmonary hypertension (CTEPH; WHO Group
IV) [1,2]. Fibrous organization of persistent pulmonary em-
boli leads to increased pulmonary vascular resistance and
promotes adverse pulmonary vascular remodeling, thus
contributing to further rises of pulmonary artery pressure.
This vicious cycle governs the clinical course of human
CTEPH including right ventricular (RV) hypertrophy and,
ultimately, progressive right heart failure. It is known that
RV dysfunction is a key determinant of patient outcome
and the leading cause of death for patients with CTEPH
[3-5]. A thorough clinical work-up is required to estab-
lish the diagnosis of CTEPH and guide patients through
either surgical and/or medical treatment. Echocardiog-
raphy is widely used to screen individuals for suspected
PH and routinely applied during clinical follow-up set-
tings. Here, we report the 5-year clinical journey of a pa-
tient with CTEPH.* Correspondence: f.weidemann@katharinen-hospital.de
1Department of Internal Medicine I - Cardiology, University of Würzburg,
Würzburg, Germany
2Comprehensive Heart Failure Center, University of Würzburg, Würzburg,
Germany
Full list of author information is available at the end of the article
© 2015 Liu et al.; licensee BioMed Central. Thi
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Case presentation
A woman aged 68 years was admitted to our hospital
due to progressive dyspnea in March 2008. She pre-
sented mild bilateral leg edema at physical examination.
The ECG showed acute right ventricular strain (SI/QIII)
and sinus tachycardia (heart rate = 120 beats/min). Blood
tests evidenced elevated serum D-dimer (2.59 mg/L, that
is, fivefold increase). Computed tomography (CT) revealed
extensive bilateral thrombi in proximal and peripheral
pulmonary arteries plus RV dilation and hypertrophy
(Figure 1A,B,C). Pulmonary function tests indicated GOLD
II chronic obstructive pulmonary disease (COPD). Arterial
blood gas analysis suggested hypocapnia and hypoxemia
(pCO2 30 mmHg; PO2 64 mmHg; O2 saturation 94%). Ini-
tial transthoracic echocardiography (TTE; Table 1) showed
a significantly dilated RV with D-shaped left ventricle (LV)
and a dilated right atrium (RA). LV and left atrium dimen-
sions as well as LV ejection fraction were normal. Doppler-
derived maximal systolic pulmonary artery pressure (SPAP)
was 69 mmHg (maximum trans-tricuspid pressure gra-
dient of 59 mmHg + estimated RA pressure of 10 mmHg).
Diagnosis of CTEPH was established by above examina-
tions and right heart catheterization examination. Others is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Computed tomography scans at first clinical presentation and 3 months later. (A) Coronal contrast-enhanced CT scan at first
clinical presentation shows a flattened eccentric thrombus in the main right pulmonary artery (black arrows). (A’) Repeat CT scan after 3 months
of treatment shows the shrunken thrombus formation (black arrow). (B, B’) Coronal contrast-enhanced CT scans at the time of first diagnosis and 3
months later show multiple filling defects both at the bifurcation and in the left pulmonary arteries (white arrows). (C, C’) Axial contrast-enhanced CT
scans show dilatation of the right ventricle (RV), dilatation of the right atrium, and thickening of the RV free wall both at initial presentation and 3
months later. LPA: left pulmonary artery; LV: left ventricle; RA: right atrium; RPA: right pulmonary artery; RV: right ventricle.
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denafil (3 × 20 mg/day), oral anticoagulation, and diuretics.
Therapy was sequentially escalated towards triple therapy
including inhaled iloprost (6 × 2.5 μg/day) and endothelin
receptor blockade with ambrisentan (1 × 10 mg/day). The
patient repeatedly refused evaluation for pulmonary end-
arterectomy (PEA) and remained clinically stable on WHO
level III for 4 years. The N-terminal of the prohormone
brain natriuretic peptide (NT-proBNP) levels also re-
mained stable initially, but increased during long-term
follow-up (from 2,400 to 14,300 pg/mL; Figure 2). The pa-
tient presented with decompensated right heart failure in
October 2012 and was evaluated for PEA and heart/lung
transplantation; however, the evaluation results were nega-
tive. After a stable period of several months under standard
medication, the patient presented again with decompen-
sated right heart failure in August 2013 and died in hos-
pital due to cardiogenic shock.
Serial TTE (Figure 3) revealed a constant elevation of
Doppler-derived SPAP with the highest value of 86
mmHg between March 2008 and April 2012. Right heart
catheterization showed correspondingly high mean pul-
monary arterial pressure of 38 to 45 mmHg at this
period (Table 1). Of note, Doppler-derived SPAP grad-
ually decreased over the last two examinations. Reducedtricuspid annular plane systolic excursion (TAPSE;
Figure 4, left) and RV fractional area (FAC) were addition-
ally seen throughout the follow-up. Two-dimensional
speckle tracking imaging (STI) revealed severely impaired
RV longitudinal function (global longitudinal strain =−11%)
with predominantly compromised function at the apex
(Figure 3, right). Additionally, tricuspid regurgitation
(TR) continuous-wave Doppler demonstrated a nomi-
nally “normal” peak pressure gradient (19 mmHg) with
a late peaking velocity spectrum at the final examina-
tion. Interestingly, a normal tricuspid pressure gradient
with a normal early peaking velocity spectrum was
shown by Doppler echocardiography performed in 2007
before the clinical event of pulmonary thromboem-
bolism (Figure 3).
NT-proBNP levels, 6-min walk distance (6MWD), and
invasive hemodynamic monitoring suggested that severe
PH existed during the whole disease journey. Extremely
enlarged RV and RA, dilated main PA diameter, and de-
creased cardiac output, as well as increased pulmonary
vascular resistance also provided circumstantial evidence
on progressive worsening in both RV volume and pres-
sure overload in this patient. However, significantly ele-
vated tricuspid pressure gradient in the early phase of
CTEPH normalized at the late phase of this patient’s
Table 1 Echocardiographic, right heart catheterization and arterial blood gas analysis characteristics
Oct-07 Mar-08 initiation Apr-09 Apr-12 Oct-12 Aug-13
Echocardiography
LVEDD (mm) 39 38 39 37 39 39
IVSd (mm) 8 8 8 8 8 8
CI (L/min,Teich) 3.16 2.71 2.46 2.31 1.61 1.86
LAD (mm) 27 29 28 28 32 30
RVD (mm) 37 46 48 51 53 48
RVd (mm) 6 7 7 7 7 7
RAA (cm2) 13 23 26 30 30 20
LV EF (%) 69 69 68 85 73 72
RV FAC (%) 46 24 20 18 18 21
MAPSE_septal (mm) 9 6 5 7 7 8
MAPSE_lateral (mm) 10 8 8 9 9 10
TAPSE (mm) 18 15 13 13 12 13
LV diastolic function abnormal relaxation abnormal relaxation - abnormal relaxation - abnormal relaxation
TR maxV (m/s) 2.5 3.8 3.8 4.2 3.0 2.2
TR maxPG (mmHg) 25 59 58 71 36 19
VTIRVOT (cm) - - 9.1 12.0 - 10.7
Estimated PVR (Woods units) - - 4.02 3.34 - 1.90
RAP (mmHg) 5 10 15 15 15 10
SPAP (mmHg) 30 69 73 86 51 29
RVOT diameter (mm) - 37 39 41 - 40
Main PA diameter (mm) - 24 24 25 - 30
Pericardial effusion (mm) 0 5 3 0 4 3
Pleural effusion - yes - - yes -
Right heart catheterization
PA mean pressure (mmHg) - 38 42 - 45 -
PA systolic pressure (mmHg) - 71 75 - 81 -
RA mean pressure (mmHg) - 4 6 - 14 -
RV systolic pressure (mmHg) - 67 75 - 84 -
PA O2 (%) - 47 53 - 51 -
Arterial blood gas analysis
PO2 (mmHg) - 64 56 59 50 58
PCO2 (mmHg) - 30 33 35 43 41
O2 saturation (%) - 94 91 93 89 93
6MWD (m) - - 200 190 - 200
Initiation represents the first hospitalization of this patient in our hospital because of progressive dyspnea. LVEDD: end-diastolic left ventricular dimension;
IVSd: end-diastolic interventricular septal thickness; LAD: end-systolic left atrial diameter; RVD: end-diastolic basal right ventricular dimension; RVd: end-diastolic
right ventricular free wall thickness; RAA: end-systolic right atrial area; LV: left ventricle; EF: ejection fraction; RV: right ventricle; FAC: fractional area change;
MAPSE: mitral annular plane systolic excursion; TAPSE: tricuspid annular plane systolic excursion; TR: tricuspid regurgitation; maxV: maximal velocity; maxPG: maximal
pressure gradient; RVOT: right ventricular outflow tract; VTI: velocity-time integral; PVR: pulmonary vascular resistance, estimated PVR by echocardiography formula:
10 × (TR maxV/VTIRVOT) − 0.16; CI: cardiac output indexed to body surface area; Woods units: mmHg⋅min/L; RAP: estimated right atrial pressure; PA: pulmonary artery;
RA: right atrium; 6MWD: 6-min walk distance test.
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normalization of SPAP during development in this pa-
tient remain an issue of speculation. This decline of thepressure gradient is not due to improvement of tricuspid
regurgitation but rather a feature of progressive right
ventricular dysfunction, as indicated by a sustained
Figure 2 Temporal changes of NT-proBNP measurements during follow-up.
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duced RV longitudinal strain in STI (Figure 3). Previous
experimental study on chronic RV pressure overload
model proved that RV systolic function is preserved, but
diastolic function is impaired. To compensate, RA con-
tractility increases to maintain filling stiffened ventricle,
and the atrium acts as a reservoir than a conduit [6]. As
time passes, RA pressure comes to be further increased
due to the exhaustion of RA contractility. When the in-
creased degree in the RA pressure is more than in the RV
pressure, the pressure difference between RV and RA (tri-
cuspid pressure gradient) will be reduced. Thus, we specu-
late that pseudo-normalization of the pressure gradient
should not be interpreted as a positive treatment response
but rather as an ominous sign of advancing right heartFigure 3 Serial echocardiographic observations of tricuspid regurgitant
trans-tricuspid pressure gradient (19 mmHg) with the pathological late-peakin
distinct from the normal pressure gradient exhibiting an early-peaking velocit
of pulmonary thromboembolism.failure owing to an exhaustion of RV and RA contractile
function. The shape of the velocity spectrum is another
important sign in this context as the late-peaking velocity
trace might be related to RV contractile dysfunction.
Additionally, we observed the discrepancy between
echocardiographic-derived SPAP (reduced) and right
heart catheterization measured pulmonary artery systolic
pressure (increased) during the late course of PH in
this patient. The underlying reason might be that
echocardiographic-derived SPAP reflects the pressure
gradient between RV and RA, which is low due to in-
creased RA pressure in this patient at late disease phase.
While invasive right heart catheterization-measured SPAP
presents the real increased pressure situation at pul-
monary artery.jet (continuous-wave Doppler recording). Note the pseudo-normal
g velocity spectrum at the final examination (August 2013), clearly
y spectrum at the examination in 2007, that is, prior to the clinical event
Figure 4 Measurements of tricuspid annular plane systolic excursion (TAPSE; left) and right ventricular longitudinal systolic strain
(LSsys; right) derived from two-dimensional speckle tracking imaging at the final examination (August 2013). Solid-colored lines indicate
corresponding segmental strain curves and white dashed line indicates global strain curve on the right panel. Note the considerably reduced
measurement values for TAPSE (normal range: >20 mm) and right ventricular global LSsys (−11%). Lat: RV lateral wall; RA: right atrium; RV: right
ventricle; Sept: interventricular septum.
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some clinical indices and other echocardiographic pa-
rameters might be additionally useful for predicting
the outcome in this case. When retrospectively
reviewing the full journey of this patient, sustained
elevated NT-proBNP levels and a significantly low
6MWD were observed. Previous studies showed that
BNP and NT-proBNP correlated well with RV function
and prognosis in several forms of pulmonary hyper-
tension [7-9]. The 6MWD has been widely used for
measuring the response to therapeutic interventions
for pulmonary and cardiac disease [8]. Our obser-
vation also demonstrated the value of monitoring
6MWD for evaluating PH disease progression. Therefore,
monitoring these clinical indices during follow-up might
be helpful for predicting the adverse outcome in
patients with CTEPH besides standard echocardio-
graphic parameters including SPAP, TAPSE, RV FAC,
and STI.Conclusions
In conclusion, “normalized” echocardiography-derived
SPAP with the progression of the disease is a feature
of progressive right heart dysfunction in patients with
CTEPH. Besides SPAP, other RV functional parame-
ters such as TAPSE, RV FAC, and RV longitudinal
strain, together with clinical markers, may provide
additionally useful guidance regarding functional im-
provement or progression in patients with CTEPH.Consent
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